10-Q
--12-31Q1Apr. 06, 20210001856725false2022-04-300001856725rani:SecondarySalesTransactionsMember2021-02-012021-02-280001856725us-gaap:CommonClassCMember2022-03-310001856725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001856725us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001856725us-gaap:GeneralAndAdministrativeExpenseMemberrani:InCubeLabsLLCMember2022-01-012022-03-310001856725us-gaap:CommonClassBMember2021-12-310001856725srt:ParentCompanyMemberus-gaap:IPOMemberus-gaap:CommonClassAMember2021-08-012021-08-310001856725us-gaap:ConvertiblePreferredStockMember2020-12-310001856725srt:ScenarioPreviouslyReportedMemberus-gaap:MemberUnitsMember2022-03-3100018567252021-08-012021-08-310001856725rani:PaycheckProtectionProgramMemberrani:LoanAndSecurityAgreementMember2020-04-012020-04-300001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-01-012022-03-310001856725us-gaap:RestrictedStockMember2022-01-012022-03-3100018567252021-01-012021-12-310001856725us-gaap:CommonClassAMember2021-12-310001856725rani:RestrictedStockAwardsMember2022-03-310001856725us-gaap:StockOptionMember2021-12-310001856725us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001856725rani:RmsIclServiceAgreementMember2022-01-012022-03-310001856725us-gaap:RetainedEarningsMember2021-12-3100018567252022-01-012022-03-310001856725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001856725rani:SeriesEWarrantsMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-03-310001856725rani:ExclusiveLicenseIntellectualPropertyAndCommonUnitPurchaseAgreementMemberrani:InCubeLabsLLCMember2022-03-310001856725rani:RaniManagementServiceAndInCubeLabsLlcMember2022-01-012022-03-310001856725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001856725us-gaap:CommonStockMember2020-12-310001856725us-gaap:InterestExpenseMember2021-01-012021-12-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001856725rani:RmsIclServiceAgreementMember2022-03-310001856725us-gaap:FairValueMeasurementsRecurringMember2022-03-310001856725us-gaap:AdditionalPaidInCapitalMember2021-12-310001856725us-gaap:StockOptionMember2022-03-310001856725us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001856725us-gaap:StockOptionMember2022-01-012022-03-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-03-310001856725us-gaap:InterestExpenseMember2021-07-012021-09-300001856725us-gaap:CommonClassAMember2022-05-090001856725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001856725srt:ScenarioPreviouslyReportedMember2022-03-310001856725rani:ClassAUnitsOfRaniLLCExchangeableForClassACommonStockMember2022-01-012022-03-310001856725us-gaap:ConvertiblePreferredStockMember2021-03-3100018567252020-12-310001856725rani:SeriesEPreferredUnitsMember2022-01-012022-03-310001856725us-gaap:CommonClassCMember2022-05-090001856725us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-12-310001856725us-gaap:AccountingStandardsUpdate201602Member2022-03-310001856725rani:PaycheckProtectionProgramMember2020-04-300001856725srt:ParentCompanyMemberus-gaap:IPOMemberus-gaap:CommonClassAMember2021-08-310001856725us-gaap:CommonClassAMember2021-01-012021-03-310001856725rani:SecondarySalesTransactionsMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-02-012021-02-280001856725us-gaap:FairValueInputsLevel3Member2021-12-310001856725rani:TakedaAgreementMember2022-01-012022-03-310001856725rani:SeriesEWarrantsMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001856725us-gaap:WarrantMemberrani:AvenueVentureOpportunityFundLPMemberrani:LoanAndSecurityAgreementMember2020-09-300001856725rani:InCubeLabsLLCMember2021-01-012021-03-310001856725us-gaap:CommonClassAMember2022-01-012022-03-3100018567252021-01-012021-03-310001856725rani:OutstandingCapitalClassAUnitMemberrani:ContinuingLlcOwnersMember2022-01-012022-03-310001856725us-gaap:RestrictedStockUnitsRSUMember2021-12-310001856725us-gaap:AdditionalPaidInCapitalMember2022-03-310001856725us-gaap:CommonClassBMember2022-05-090001856725rani:RaniLLCMember2022-03-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001856725rani:AvenueVentureOpportunityFundLPMemberrani:LoanAndSecurityAgreementMember2021-07-310001856725rani:PaycheckProtectionProgramMember2020-04-012020-04-300001856725us-gaap:ConvertiblePreferredStockMember2021-01-012021-03-310001856725us-gaap:CommonClassAMember2022-03-310001856725rani:RmsIclServiceAgreementMember2021-01-012021-03-310001856725srt:ParentCompanyMemberus-gaap:CommonClassAMember2021-08-310001856725rani:TakedaAgreementMember2021-01-012021-03-310001856725rani:ContinuingLlcOwnersMember2021-08-310001856725rani:PairedInterestsMember2022-01-012022-03-310001856725us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001856725us-gaap:FairValueMeasurementsRecurringMember2021-12-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-12-310001856725us-gaap:RetainedEarningsMember2020-12-310001856725srt:ParentCompanyMember2022-01-012022-03-310001856725us-gaap:FairValueInputsLevel3Member2021-03-310001856725us-gaap:StockOptionMember2022-01-012022-03-310001856725us-gaap:RetainedEarningsMember2022-01-012022-03-310001856725us-gaap:RestrictedStockMember2022-03-310001856725rani:TakedaAgreementMember2021-05-310001856725rani:SecondarySalesTransactionsMemberus-gaap:GeneralAndAdministrativeExpenseMember2021-02-012021-02-280001856725us-gaap:RestrictedStockMember2022-01-012022-03-310001856725us-gaap:NoncontrollingInterestMember2021-12-310001856725srt:ParentCompanyMemberus-gaap:CommonClassAMember2021-08-012021-08-310001856725us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-03-310001856725us-gaap:GeneralAndAdministrativeExpenseMemberrani:InCubeLabsLLCMember2021-01-012021-03-310001856725us-gaap:ResearchAndDevelopmentExpenseMemberrani:InCubeLabsLLCMember2022-01-012022-03-310001856725us-gaap:FairValueInputsLevel3Member2022-03-310001856725us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001856725rani:RestrictedStockAwardsMember2022-01-012022-03-310001856725us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-310001856725us-gaap:CommonClassCMember2021-12-310001856725us-gaap:WarrantMembersrt:MaximumMemberrani:AvenueVentureOpportunityFundLPMemberrani:LoanAndSecurityAgreementMember2020-09-300001856725us-gaap:CommonClassCMembersrt:ParentCompanyMember2021-08-012021-08-310001856725srt:ParentCompanyMemberus-gaap:CommonClassBMember2021-08-012021-08-3100018567252022-03-310001856725rani:RaniLLCMemberus-gaap:CommonClassAMember2022-03-310001856725srt:MinimumMemberrani:PairedInterestMember2022-03-310001856725us-gaap:WarrantMemberrani:LoanAndSecurityAgreementMemberrani:AvenueVentureOpportunityFundLPMember2020-09-012020-09-300001856725us-gaap:CommonStockMember2021-03-310001856725us-gaap:CommonClassBMember2022-03-310001856725rani:PaycheckProtectionProgramMemberrani:LoanAndSecurityAgreementMemberrani:AvenueVentureOpportunityFundLPMember2021-09-300001856725us-gaap:StockOptionMember2021-01-012021-12-310001856725rani:AvenueVentureOpportunityFundLPMemberrani:LoanAndSecurityAgreementMember2021-07-012021-07-310001856725srt:MaximumMemberrani:PairedInterestMember2022-03-310001856725us-gaap:ResearchAndDevelopmentExpenseMemberrani:InCubeLabsLLCMember2021-01-012021-03-310001856725us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001856725us-gaap:NoncontrollingInterestMember2022-03-310001856725us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001856725rani:SecondarySalesTransactionsMember2021-02-280001856725us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-01-012022-03-310001856725us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001856725us-gaap:RetainedEarningsMember2022-03-310001856725us-gaap:CommonClassAMemberrani:RaniLLCMember2022-03-3100018567252021-12-310001856725us-gaap:WarrantMembersrt:MinimumMemberrani:LoanAndSecurityAgreementMemberrani:AvenueVentureOpportunityFundLPMember2020-09-300001856725us-gaap:WarrantMemberrani:SeriesEPreferredUnitsMemberrani:AvenueVentureOpportunityFundLPMemberrani:LoanAndSecurityAgreementMember2020-09-012020-09-300001856725us-gaap:CapitalUnitClassAMemberrani:ContinuingLlcOwnersMember2022-01-012022-03-310001856725us-gaap:RestrictedStockMember2021-12-310001856725rani:TaxReceivableAgreementMember2022-01-012022-03-3100018567252021-03-310001856725us-gaap:CommonStockMember2021-01-012021-03-310001856725srt:ScenarioPreviouslyReportedMemberus-gaap:ConvertiblePreferredStockMember2022-03-310001856725us-gaap:RetainedEarningsMember2021-03-310001856725us-gaap:FairValueInputsLevel3Member2020-12-310001856725rani:TakedaAgreementMember2017-11-300001856725us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001856725us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-03-310001856725rani:RaniLlcIclServiceAgreementMember2022-03-310001856725rani:InCubeLabsLLCMember2022-01-012022-03-310001856725us-gaap:RestrictedStockUnitsRSUMember2022-03-310001856725rani:TakedaAgreementMember2017-11-012017-11-300001856725us-gaap:RetainedEarningsMember2021-01-012021-03-310001856725us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001856725rani:RaniLLCMember2022-03-31xbrli:purerani:Segmentxbrli:sharesiso4217:USDxbrli:sharesiso4217:USD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________ to ________________

Commission File Number: 001-40672

 

RANI THERAPEUTICS HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

86-3114789

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

2051 Ringwood Avenue

San Jose, California

95131

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (408) 457-3700

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Class A common stock, par value $0.0001 per share

 

RANI

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

Non-accelerated filer

 

 

Smaller reporting company

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No ☒

As of May 9, 2022, the registrant had 24,488,633 shares of Class A common stock, $0.0001 par value per share, outstanding, 24,671,683 shares of Class B common stock, $0.0001 par value per share, outstanding and no shares of Class C common stock, $0.0001 par value per share, outstanding. Certain holders of units of the registrant’s consolidated subsidiary, Rani Therapeutics, LLC, who do not hold shares of the registrant’s Class B common stock can exchange their units of Rani Therapeutics, LLC for 1,387,471 shares of the registrant’s Class A common stock.

 

 


 

Table of Contents

 

 

 

Page

Special Note Regarding Forward-Looking Statements

3

 

 

 

PART I.

FINANCIAL INFORMATION

 

 

 

 

 

RANI THERAPEUTICS HOLDINGS, INC.

 

Item 1.

Financial Statements (Unaudited)

5

 

Condensed Consolidated Balance Sheets

5

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

6

 

Condensed Consolidated Statements of Changes in Stockholders’ Equity/Convertible Preferred Units and Members' Deficit

7

 

Condensed Consolidated Statements of Cash Flows

8

 

Notes to Unaudited Condensed Consolidated Financial Statements

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

23

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

33

Item 4.

Controls and Procedures

33

 

 

 

PART II.

OTHER INFORMATION

35

 

 

 

Item 1.

Legal Proceedings

35

Item 1A.

Risk Factors

35

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

35

Item 3.

Defaults Upon Senior Securities

35

Item 4.

Mine Safety Disclosures

35

Item 5.

Other Information

35

Item 6.

Exhibits

36

Signatures

37

 

2


 

Unless otherwise stated or the context otherwise requires, the terms “we,” “us,” and “our,” and similar references refer to Rani Therapeutics Holdings, Inc. (“Rani Holdings”) and its consolidated subsidiaries, Rani Therapeutics, LLC (“Rani LLC”) and Rani Management Systems, Inc. (“RMS”).

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, including the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations," contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and consolidated financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, manufacturing costs, regulatory approvals, development and advancement of our oral delivery technology, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” “seek,” “aim,” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

 

the progress and focus of our current and future clinical trials in the United States and abroad, and the reporting of data from those trials;
our ability to advance product candidates into and successfully complete clinical trials;
the beneficial characteristics, safety, efficacy, and therapeutic effects of our product candidates;
our potential and ability to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved;
our ability to develop RaniPill HC or any redesign and conduct additional preclinical and clinical studies of any future design of the RaniPill capsule to accommodate target payloads that are larger than the payload capacity of the RaniPill capsule currently used for our product candidates;
our ability to further develop and expand our platform technology;
our ability to utilize our technology platform to generate and advance additional product candidates;
the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;
our financial performance;
our plans relating to commercializing our product candidates, if approved;
our ability to selectively enter into strategic partnership and the expected potential benefits thereof;
the implementation of our strategic plans for our business and product candidates;
our ability to continue to scale and optimize our manufacturing processes by expanding our use of automation;
our estimates of the number of patients in the United States who suffer from the indications we target and the number of patients that will enroll in our clinical trials;
the size of the market opportunity for our product candidates in each of the indications we target;
our ability to continue to innovate and expand our intellectual property by developing novel formulations and new applications of the RaniPill capsule;
our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;
the scope of protection we are able to establish and maintain for intellectual property rights, including our technology platform and product candidates;

3


 

the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements;
our expectations regarding the impact of the COVID-19 pandemic and the conflict between Ukraine and Russia on our business;
developments relating to our competitors and our industry, including competing product candidates and therapies; and
our expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”).

These forward-looking statements are subject to a number of risks, uncertainties, and assumptions described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.

4


 

RANI THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value)

 

 

 

March 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

107,839

 

 

$

117,453

 

Prepaid expenses

 

 

1,421

 

 

 

2,142

 

Total current assets

 

 

109,260

 

 

 

119,595

 

Property and equipment, net

 

 

4,890

 

 

 

4,612

 

Operating lease right-of-use asset

 

 

1,159

 

 

 

 

Total assets

 

$

115,309

 

 

$

124,207

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

1,265

 

 

$

1,080

 

Related party payable

 

 

140

 

 

 

126

 

Accrued expenses

 

 

2,101

 

 

 

1,434

 

Operating lease liability, current portion

 

 

650

 

 

 

 

Total current liabilities

 

 

4,156

 

 

 

2,640

 

Operating lease liability, net current portion

 

 

509

 

 

 

 

Total liabilities

 

 

4,665

 

 

 

2,640

 

Commitments and contingencies (Note 10)

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of March 31, 2022 and December 31, 2021

 

 

 

 

 

 

Class A common stock, $0.0001 par value - 800,000 shares authorized; 24,387 and 19,712 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively

 

 

2

 

 

 

2

 

Class B common stock, $0.0001 par value - 40,000 shares authorized; 24,773 and 29,290 issued and outstanding as of March 31, 2022 and December 31, 2021, respectively

 

 

3

 

 

 

3

 

Class C common stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of March 31, 2022 and December 31, 2021

 

 

 

 

 

 

Additional paid-in capital

 

 

67,933

 

 

 

55,737

 

Accumulated deficit

 

 

(14,554

)

 

 

(8,331

)

Total stockholders' equity attributable to Rani Therapeutics Holdings, Inc.

 

 

53,384

 

 

 

47,411

 

Non-controlling interest

 

 

57,260

 

 

 

74,156

 

Total stockholders' equity

 

 

110,644

 

 

 

121,567

 

Total liabilities and stockholders' equity

 

$

115,309

 

 

$

124,207

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5


 

RANI THERAPEUTICS HOLDINGS, INC.

CONDENSED Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Contract revenue

 

$

 

 

$

756

 

Operating expenses

 

 

 

 

 

 

Research and development

 

 

7,591

 

 

 

3,347

 

General and administrative

 

 

6,189

 

 

 

2,607

 

Total operating expenses

 

$

13,780

 

 

$

5,954

 

Loss from operations

 

 

(13,780

)

 

 

(5,198

)

Other income (expense), net

 

 

 

 

 

 

Interest income

 

 

15

 

 

 

47

 

Interest expense and other, net

 

 

 

 

 

(188

)

Change in estimated fair value of preferred unit warrant

 

 

 

 

 

(216

)

Loss before income taxes

 

 

(13,765

)

 

 

(5,555

)

Income tax expense

 

 

(63

)

 

 

(43

)

Net loss and comprehensive loss

 

$

(13,828

)

 

$

(5,598

)

Net loss attributable to non-controlling interest

 

 

(7,605

)

 

 

(5,598

)

Net loss attributable to Rani Therapeutics Holdings, Inc.

 

$

(6,223

)

 

$

 

Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., basic and diluted

 

$

(0.29

)

 

 

 

Weighted-average Class A common shares outstanding—basic and diluted

 

 

21,409

 

 

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

6


 

RANI THERAPEUTICS HOLDINGS, INC.

CONDENSED Consolidated Statements of Changes in STOCKHOLDERS’ Equity/CONVERTIBLE PREFERRED UNITS AND MEMBERS' Deficit

(in thousands)

(Unaudited)

 

 

 

Class A Common Stock

 

 

Class B Common Stock

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Additional Paid In Capital

 

 

Accumulated Deficit

 

 

Non-Controlling Interest

 

 

Total Stockholders' Equity

 

Balance at December 31, 2021

 

 

19,712

 

 

$

2

 

 

 

29,290

 

 

$

3

 

 

$

55,737

 

 

$

(8,331

)

 

$

74,156

 

 

$

121,567

 

Effect of exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC

 

 

4,675

 

 

 

 

 

 

(4,517

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-controlling interest adjustment for changes in proportionate ownership in Rani LLC

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10,928

 

 

 

 

 

 

(10,928

)

 

 

 

Equity-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,268

 

 

 

 

 

 

1,637

 

 

 

2,905

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6,223

)

 

 

(7,605

)

 

 

(13,828

)

Balance at March 31, 2022

 

 

24,387

 

 

$

2

 

 

 

24,773

 

 

$

3

 

 

$

67,933

 

 

$

(14,554

)

 

$

57,260

 

 

$

110,644

 

 

 

 

Convertible Preferred

 

 

 

Common

 

 

 

 

 

 

 

 

 

Units

 

 

Amount

 

 

 

Units

 

 

Amount

 

 

Accumulated
Deficit

 

 

Total Members’
Deficit

 

Balance at December 31, 2020

 

 

26,746

 

 

$

184,714

 

 

 

 

46,890

 

 

$

664

 

 

$

(114,003

)

 

$

(113,339

)

Issuance of Series E preferred units

 

 

884

 

 

 

6,320

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercise of warrant for common units

 

 

 

 

 

 

 

 

 

6

 

 

 

13

 

 

 

 

 

 

13

 

Equity-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

453

 

 

 

 

 

 

453

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5,598

)

 

 

(5,598

)

Balance at March 31, 2021

 

 

27,630

 

 

$

191,034

 

 

 

 

46,896

 

 

$

1,130

 

 

$

(119,601

)

 

$

(118,471

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

7


 

RANI THERAPEUTICS HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2022

 

 

2021

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$

(13,828

)

 

$

(5,598

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

111

 

 

 

136

 

Equity-based compensation expense

 

 

2,905

 

 

 

453

 

Change in fair value of preferred unit warrant liability

 

 

 

 

 

216

 

Non-cash operating lease expense

 

 

157

 

 

 

 

Other

 

 

 

 

 

67

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other assets

 

 

721

 

 

 

27

 

Accounts payable

 

 

78

 

 

 

385

 

Accrued expenses

 

 

639

 

 

 

821

 

Operating lease liabilities

 

 

(157

)

 

 

 

Related party payable

 

 

14

 

 

 

201

 

Deferred revenue

 

 

 

 

 

(756

)

Net cash used in operating activities

 

 

(9,360

)

 

 

(4,048

)

Cash flows from investing activities

 

 

 

 

 

 

Purchases of property and equipment

 

 

(254

)

 

 

(99

)

Net cash used in investing activities

 

 

(254

)

 

 

(99

)

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from issuance of preferred units, net of issuance costs

 

 

 

 

 

6,320

 

Proceeds from exercise of warrants for common units

 

 

 

 

 

13

 

Payment of deferred offering costs

 

 

 

 

 

(302

)

Principal and interest repayments from related party for note receivable

 

 

 

 

 

1,720

 

Net cash provided by financing activities

 

 

 

 

 

7,751

 

Net (decrease) increase in cash and cash equivalents

 

 

(9,614

)

 

 

3,604

 

Cash and cash equivalents, beginning of period

 

 

117,453

 

 

 

73,058

 

Cash and cash equivalents, end of period

 

$

107,839

 

 

$

76,662

 

Supplemental disclosures of non-cash investing and financing activities

 

 

 

 

 

 

Property and equipment purchases included in accounts payable and accrued expenses

 

$

135

 

 

$

58

 

Exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC

 

$

73,160

 

 

$

 

Deferred financing costs included in accrued expenses

 

$

 

 

$

483

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

8


 

RANI THERAPEUTICS HOLDINGS, INC.

Notes to THE UNAUDITED CONDENSED Consolidated Financial Statements

1. Organization and Nature of Business

Description of Business

Rani Therapeutics Holdings, Inc. (“Rani Holdings”) was formed as a Delaware corporation in April 2021 for the purpose of facilitating an initial public offering (“IPO”) of its Class A common stock, and to facilitate certain organizational transactions and to operate the business of Rani Therapeutics, LLC (“Rani LLC”) and its consolidated subsidiary, Rani Management Services, Inc. (“RMS”). Rani Holdings and its consolidated subsidiaries, Rani LLC and RMS are collectively referred to herein as “Rani” or the “Company.”

The Company is a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The Company is advancing a portfolio of oral biologic therapeutics using its proprietary delivery technology, the RaniPill capsule. The Company is headquartered in San Jose, California and operates in one segment.

Initial Public Offering and Organizational Transactions

In August 2021, the Company closed its IPO and sold 7,666,667 shares of its Class A common stock, including shares issued pursuant to the exercise in full of the underwriters’ option, for cash consideration of $11.00 per share and received approximately $73.6 million in net proceeds, after deducting underwriting discounts, offering costs and commissions. The Company used the proceeds from the IPO to purchase 7,666,667 newly issued economic nonvoting Class A units (“Class A Units”) of Rani LLC.

In connection with the IPO, the Company was party to the following organizational transactions (the “Organizational Transactions”):

Amended and restated Rani LLC’s operating agreement (the “Rani LLC Agreement”) to appoint the Company as the sole managing member of Rani LLC and effectuated an exchange of all outstanding (i) convertible preferred units, automatic or net exercised warrants to purchase preferred units and common units, and common units of Rani LLC, into Class A Units and an equal number of voting noneconomic Class B units (“Class B Units”) and (ii) all Profits Interests into Class A Units. In connection with the closing of the IPO, each LLC interest was exchanged 1 for 0.5282 as determined and predicated on the initial public offering price of the Company’s Class A common stock;
Amended and restated the Company’s certificate of incorporation in July 2021, to provide for the issuance of (i) Class A common stock, each share of which entitles its holders to one vote per share, (ii) Class B common stock, each share of which entitles its holders to 10 votes per share on all matters presented to the Company's stockholders, (iii) Class C common stock, which has no voting rights, except as otherwise required by law and (iv) preferred stock;
Exchanged 12,047,925 shares of Class A common stock for existing Class A Units of Rani LLC held by certain individuals and entities (the “Former LLC Owners”) on a one-for-one basis;
Issued 29,290,391 shares of Class B common stock to certain individuals and entities that continued to hold Class A Units in Rani LLC after the IPO (the “Continuing LLC Owners”) in return for an equal amount of Rani LLC Class B Units;
Entered into a Registration Rights Agreement with certain of the Continuing LLC Owners.

The Continuing LLC Owners are entitled to exchange, subject to the terms of the Rani LLC Agreement, the Class A Units they hold in Rani LLC, together with the shares they hold of the Company Class B common stock (together referred to as a "Paired Interest"), in return for shares of the Company’s Class A common stock on a one-for-one basis provided that, at the Company’s election, the Company has the ability to effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed. Any shares of Class B common stock will be cancelled on a one-for-one basis if, at the election of the Continuing LLC Owners, the Company redeems or exchanges such Paired Interest pursuant to the terms of the Rani LLC Agreement. As of March 31, 2022, certain individuals who continue to own interests in Rani LLC but do not hold shares of the Company’s Class B common stock (“non-corresponding Class A Units”) have the ability to exchange their non-corresponding Class A Units of Rani LLC for 1,387,471 shares of the Company’s Class A common stock.

9


 

Liquidity

The Company has incurred recurring losses since its inception, including net losses of $13.8 million for the three months ended March 31, 2022. As of March 31, 2022, the Company had an accumulated deficit of $14.6 million and for the three months ended March 31, 2022 had negative cash flows from operations of $9.4 million. The Company expects to continue to generate operating losses and negative operating cash flows for the foreseeable future as it continues to develop the RaniPill capsule. The Company expects that its cash and cash equivalents of $107.8 million as of March 31, 2022 will be sufficient to fund its operations through at least twelve months from the date the condensed consolidated financial statements are issued. The Company expects to finance its future operations with its existing cash and through strategic financing opportunities that could include, but are not limited to, future offerings of its equity, collaboration or licensing agreements, or the incurrence of debt. However, there is no guarantee that any of these strategic or financing opportunities will be executed or realized on favorable terms, if at all, and some could be dilutive to existing stockholders and holders of interests in the Company. The Company will not generate any revenue from product sales unless, and until, it successfully completes clinical development and obtains regulatory approval for the RaniPill capsule. If the Company obtains regulatory approval for the RaniPill capsule, it expects to incur significant expenses related to developing its internal commercialization capability to support manufacturing, product sales, marketing, and distribution.

The Company’s ability to raise additional capital through either the issuance of equity or debt, is dependent on a number of factors including, but not limited to, the market interest of the Company, which itself is subject to a number of development and business risks and uncertainties, as well as the uncertainty that the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. Market volatility resulting from the novel coronavirus disease (“COVID-19”) pandemic or other factors could also adversely impact the Company’s ability to access capital when and as needed.

 

2. Summary of Significant Accounting Policies

Basis of Presentation

These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

The Company operates and controls all of the business and affairs of Rani LLC, and through Rani LLC and its subsidiary, conducts its business. Because the Company manages and operates the business and controls the strategic decisions and day-to-day operations of Rani LLC and also has a substantial financial interest in Rani LLC, the Company consolidates the financial results of Rani LLC, and a portion of its net loss is allocated to the non-controlling interests in Rani LLC held by the Continuing LLC Owners. All intercompany accounts and transactions have been eliminated in consolidation.

The Organizational Transactions were considered transactions between entities under common control. As a result, the condensed consolidated financial statements for periods prior to the IPO and the Organizational Transactions have been adjusted to combine the previously separate entities for presentation purposes.

 

Unaudited Interim Condensed Consolidated Financial Statements

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state the financial position and the results of the Company's operations and cash flows for interim periods in accordance with U.S. GAAP. All such adjustments are of a normal, recurring nature except for the adoption of the new lease accounting standard. Operating results for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022 or for any future period.

The consolidated balance sheet as of December 31, 2021 included herein was derived from the audited consolidated financial statements as of that date. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Therefore, these interim condensed consolidated financial statements should be read in conjunction with the 2021 consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2022.

 

10


 

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Estimates include, but are not limited to equity-based compensation expense, accrued research and development costs and, until the occurrence of the Company's IPO, the fair value of Profits Interests and preferred unit warrants. Actual results may differ materially and adversely from these estimates.

 

Significant Accounting Policies

A description of the Company’s significant accounting policies is included in the audited consolidated financial statements within its Annual Report on Form 10-K for the year ended December 31, 2021. Except as noted below, there have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2022.

Concentrations of Credit Risk and Other Risks and Uncertainties

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions in excess of federally insured limits. The Company also holds money market funds that are not federally insured. However, management believes the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which these deposits are held and of the money market funds and other entities in which these investments are made.

In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The extent to which the COVID-19 pandemic will further directly or indirectly impact the Company's results of operation and financial condition has been and will continue to be driven by many factors, most of which are beyond the Company's control and ability to forecast. Because of these uncertainties, the Company cannot estimate how long or to what extent COVID-19 will impact the Company's operations.

Fair Value of Financial Instruments

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The carrying values of the Company’s cash equivalents, prepaid expenses, accounts payable, and accruals approximate their fair value due to their short-term nature.

Leases

Prior to January 1, 2022, the Company had one cancelable operating lease agreement for its corporate headquarters and recognized related rent expense on a straight-line basis over the term of the lease. The Company’s lease agreement contained termination and renewal options. The Company did not assume termination nor renewals options in its determination of the lease term

11


 

unless they were deemed to be reasonably certain at the renewal of the lease. The Company began recognizing rent expense on the date that it obtained the legal right to use and control the leased space.

Subsequent to the adoption of the new leasing standard on January 1, 2022, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement and if such a lease is classified as a financing lease or operating lease. The Company has elected not to recognize on the balance sheet leases with terms of one year or less. For any arrangement that is considered to be a lease with a term greater than one year, the Company recognizes a lease asset for its right to use the underlying asset and a lease liability for the corresponding lease obligation. Operating leases are included in operating lease right-of-use ("ROU") assets and operating lease liabilities in the Company’s condensed consolidated balance sheet as of March 31, 2022.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease contract. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the expected lease term. In determining the net present value of lease payments, the interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate (“IBR”), which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the ROU asset may be required for items such as initial direct costs paid or incentives received and impairment charges if we determine the ROU asset is impaired. The Company considers a lease term to be the noncancelable period during which it has the right to use the underlying asset, including any periods where it is reasonably certain the Company will exercise the option to extend the contract. Periods covered by an option to extend are included in the lease term if the lessor controls the exercise of that option.

The operating lease ROU assets also include any lease payments made and exclude lease incentives. Lease expense is recognized on a straight-line basis over the expected lease term. The Company has elected to not separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its agreements as a single lease component. The lease components resulting in a ROU asset have been recorded on the condensed consolidated balance sheet and amortized as lease expense on a straight-line basis over the lease term.

Tax Receivable Agreement

In August 2021, in connection with the IPO and Organizational Transactions, the Company entered into a tax receivable agreement ("TRA") with certain of the Continuing LLC Owners. The TRA provides that the Company pay to such Continuing LLC Owners, 85% of the amount of tax benefits, if any, it is deemed to realize (calculated using certain assumptions) as a result of (i) increases in the tax basis of assets of Rani LLC resulting from (a) any future redemptions or exchanges of Paired Interests or non-corresponding Class A Units of Rani LLC and (b) payments under the TRA and (ii) certain other benefits arising from payments under the TRA (collectively the “Tax Attributes”).

A liability for the payable to parties subject to the TRA, and a reduction to stockholders’ equity, is accrued when (i) an exchange of a Paired Interest or non-corresponding Class A Units of Rani LLC has occurred and (ii) when it is deemed probable that the Tax Attributes associated with the exchange will be used to reduce the Company’s taxable income based on the contractual percentage of the benefit of Tax Attributes that the Company expects to receive over a period of time (Note 10).

Comprehensive Loss

Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions and other events and/or circumstances from non-owner sources. The Company did not have any other comprehensive loss for any of the periods presented, and therefore comprehensive loss was the same as the Company’s net loss.

12


 

Net Loss Per Class A Common Share Attributable to Rani Holdings

Basic net loss per Class A common share attributable to Rani Holdings is computed by dividing net loss attributable to the Company by the weighted average number of Class A common shares outstanding during the period, without consideration of potential dilutive securities. Diluted net loss per Class A common share is computed giving effect to all potentially dilutive shares. Diluted net loss per Class A common share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. Net loss per share is not presented for the three months ended March 31, 2021 as the Company did not have any economic interests prior to the date of the IPO and Organizational Transactions through which it was given ownership in Rani LLC. Losses prior to the IPO and Organizational Transactions would have been allocated to the original members of Rani LLC. The basic and diluted net loss per Class A common share attributable to Rani Holdings is applicable only for the periods following the IPO and Organizational Transactions and represents the periods that the Company had Class A common shares outstanding.

Non-Controlling Interest

Non-controlling interest ("NCI") represents the portion of income or loss, net assets and comprehensive loss of the Company's consolidated subsidiary that is not allocable to Rani Holdings based on the Company's percentage of ownership of Rani LLC.

In August 2021, based on the Organizational Transactions, Rani Holdings became the sole managing member of Rani LLC. As of March 31, 2022, Rani Holdings held approximately 48% of the Class A Units of Rani LLC, and approximately 52% of the outstanding Class A Units of Rani LLC are held by the Continuing LLC Owners. Therefore, the Company reports NCI based on the Class A Units of Rani LLC held by the Continuing LLC Owners on its condensed consolidated balance sheet as of March 31, 2022. Income or loss attributed to the NCI in Rani LLC is based on the Class A Units outstanding during the period for which the income or loss is generated and is presented on the condensed consolidated statements of operations and comprehensive income or loss.

Future exchanges of Paired Interests and non-corresponding Class A Units of Rani LLC will result in a change in ownership and reduce or increase the amount recorded as NCI and increase or decrease additional paid-in-capital when Rani LLC has positive or negative net assets, respectively. From the date of the Organizational Transactions to March 31, 2022, there were 4,517,105 exchanges of Paired Interests and 158,051 exchanges of non-corresponding Class A Units of Rani LLC for an equal number of shares of the Company's Class A common stock.

Recently Adopted Accounting Pronouncements

In February 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU 2016-02, Leases (“Topic 842”), as subsequently amended, to improve financial reporting and disclosures about leasing transactions. The Company adopted this standard on January 1, 2022 using the modified retrospective approach and elected the package of practical expedients permitted under transition guidance, which allowed the Company to carry forward its historical assessments of: 1) whether contracts are or contain leases, 2) lease classification and 3) initial direct costs, where applicable. The Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date and did not elect the practical expedient pertaining to land easements as this is not applicable to the current contract portfolio. The Company elected the post-transition practical expedient to not separate lease components from non-lease components for all existing lease classes. The Company also elected a policy of not recording leases on its condensed balance sheets when the leases have a term of twelve months or less and the Company is not reasonably certain to elect an option to purchase the leased asset.

The adoption of this standard resulted in the recognition of a ROU asset and lease liabilities of $1.3 million, respectively. The adoption of the standard had no impact on the Company’s condensed consolidated statements of operations and comprehensive loss or to its cash flows from or used in operating, financing, or investing activities on its condensed consolidated statements of cash flows. No cumulative-effect adjustment within accumulated deficit was required to be recorded as a result of adopting this standard.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (“ASU 2016-13”) to require the measurement of expected credit losses for financial instruments held at the reporting date based on historical experience, current conditions and reasonable forecasts. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments to extend credit held by a reporting entity at each reporting date. As a result of the Company having elected the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act, and assuming the Company continues to be

13


 

considered an emerging growth company, ASU 2016-13 will be effective for the Company on January 1, 2023. The Company has not yet determined the potential effects of ASU 2016-13 on its condensed consolidated financial statements and disclosures.

 

3. Fair Value Measurements

The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of inputs used in such measurements (in thousands):

 

 

 

As of March 31, 2022

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

105,795

 

 

$

 

 

$

 

 

$

105,795

 

Total assets

 

$

105,795

 

 

$

 

 

$

 

 

$

105,795

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2021

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

115,595

 

 

$

 

 

$

 

 

$

115,595

 

Total assets

 

$

115,595

 

 

$

 

 

$

 

 

$

115,595

 

 

Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $1.00 net asset value representing its estimated fair value.

There were no transfers between Level 1, Level 2 and Level 3 of the fair value hierarchy for any of the periods presented.

 

The Company held a Level 3 liability associated with preferred unit warrants that were issued in conjunction with a loan and security Agreement. These preferred unit warrants were settled with Class A common stock as part of the IPO and Organizational Transactions.

The following tables set forth a summary of the changes in the fair value of the Company’s liability measured using Level 3 inputs (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2022

 

 

2021

 

Balance at beginning of period

 

$

 

 

$

320

 

Change in estimated fair value of Series E warrants

 

 

 

 

 

216

 

Balance at end of period

 

$

 

 

$

536

 

 

4. Accrued Expenses

Accrued expenses consist of the following (in thousands):

 

 

 

March 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Payroll and related

 

$

1,250

 

 

$

202

 

Accrued preclinical and clinical trial costs

 

 

389

 

 

 

621

 

Accrued professional fees

 

 

323

 

 

 

213

 

Other

 

 

139

 

 

 

398

 

Total accrued expenses

 

$

2,101

 

 

$

1,434

 

 

5. Evaluation Agreement

Takeda

Takeda Pharmaceutical Company, Limited ("Takeda") was collaborating with the Company to conduct research on the use of the RaniPill capsule for the oral delivery of factor VIII (“FVIII”) therapy for patients with hemophilia A. The agreement granted Takeda a right of first negotiation to a worldwide, exclusive license under the Company’s intellectual property related to a

14


 

FVIII-RaniPill therapeutic. Takeda paid the Company up-front payments of $5.9 million upon execution of and subsequent modifications to the agreement. Upon the initial evaluation services being completed, Takeda had an option to pay the Company $3.0 million to perform later stage evaluation services. Takeda also had the ability to terminate the agreement at any time by providing 30 days written notice after the effective date of the agreement. Unless terminated early, the agreement term ended upon the expiration of the right of first negotiation period which is 120 days after the completion of the evaluation services. The Takeda agreement could be terminated for cause by either party based on uncured material breach by the other party or bankruptcy of the other party. Upon early termination, all ongoing activities under the agreement and all mutual collaboration, development and commercialization licenses and sublicenses would terminate.

The Company identified one material promise under the Takeda agreement, the obligation to perform services to evaluate if Takeda’s FVIII therapy can be orally delivered using the RaniPill capsule (“Research and Development Services”), which was concluded to be a single performance obligation.

In May 2021, the Company received written notice from Takeda as to their intent to terminate the contract for convenience. Due to the delivery of the termination notice, the Company determined that there were no further enforceable rights and obligations under the agreement beyond May 2021 and the remaining $2.0 million of deferred revenue was recognized in 2021.

For the three months ended March 31, 2022, no contract revenue related to the Takeda agreement was recognized. For three months ended March 31, 2021, the Company recognized contract revenue related to the Takeda agreement of $0.8 million. There was no deferred revenue as of March 31, 2022 nor December 31, 2021.

 

6. Related Party Transactions

InCube Labs, LLC (“ICL”) is wholly-owned by the Company’s founder and Chairman and his family. The founder and Chairman is the father of the Company’s Chief Executive Officer. The Company’s Chief Scientific Officer is also the brother of the founder and Chairman and thus uncle of the Company’s Chief Executive Officer.

Services agreements

In June 2021, Rani LLC entered into a service agreement with ICL effective retrospectively to January 1, 2021, and subsequently amended such agreement in March 2022 (as amended, the "Rani LLC-ICL Service Agreement"), pursuant to which Rani LLC and ICL agreed to provide personnel services to the other upon requests. Under the amendment in March 2022, Rani LLC has a right to occupy certain facilities leased by ICL in Milpitas, California and San Antonio, Texas (“Occupancy Services”) for general office, research and development, and light manufacturing. The Rani LLC-ICL Service Agreement has a twelve-month term and will automatically renew for a successive twelve-month periods unless terminated; except that the Occupancy Services in Milpitas, California have a term until February 2023, with the potential for two annual renewals, subject to approval by ICL upon a nine months’ notice of renewal prior to the end of the lease term, and the Occupancy Services in San Antonio, Texas continue until either party gives six months’ notice of termination. Except for the Occupancy Services, Rani LLC or ICL may terminate services under the Rani LLC-ICL Service Agreement upon 60 days' notice to the other party. The Rani LLC-ICL Service Agreement specifies the scope of services to be provided as well as the methods for determining the costs of services. Costs are billed or charged on a monthly basis by ICL or Rani LLC, respectively.

In June 2021, RMS entered into a service agreement with ICL (the “RMS-ICL Service Agreement”) effective retrospectively to January 1, 2021, pursuant to which ICL agreed to rent a specified portion of its facility in San Jose, California to RMS. Additionally, RMS and ICL agreed to provide personnel services to the other upon requests based on rates specified in the RMS-ICL Service Agreement. The RMS-ICL Service Agreement has a twelve-month term and will automatically renew for successive twelve-month periods unless terminated. RMS or ICL may terminate services under the RMS-ICL Service Agreement upon 60 days' notice to the other party, except for occupancy which requires six months’ notice. The RMS-ICL Service Agreement specifies the scope of services to be provided as well as the methods for determining the costs of services. Costs are billed or charged on a monthly basis by ICL or RMS, respectively, as well as allocations of expenses based upon RMS’s utilization of ICL’s facilities and equipment.

15


 

The table below details the amounts charged by ICL for services and rent, net of the amount that the Company charged ICL, which is included in the condensed consolidated statements of operations and comprehensive loss (in thousands):

 

 

 

Three Months Ended
March 31,

 

 

 

2022

 

 

2021

 

Research and development

 

$

239

 

 

$

33

 

General and administrative

 

 

63

 

 

 

182

 

Total

 

$

302

 

 

$

215

 

 

The Company’s eligible employees are permitted to participate in ICL’s 401(k) Plan (“401(k) Plan”). Participation in the 401(k) Plan is offered for the benefit of the employees, including the Company’s named executive officers, who satisfy certain eligibility requirements.

As of March 31, 2022, all of the Company's facilities are owned or leased by an entity affiliated with the Company’s Chairman (Note 7). The Company pays for the use of these facilities through its services agreements with ICL.

Financing activity

From inception to the first half of 2017, the Company advanced funds to ICL, and ICL made payments directly to certain vendors on behalf of Rani, Rani has reimbursed ICL for all such payments at cost on a monthly basis.

In March 2021, an outstanding notes receivable balance totaling $1.7 million, including all accrued interest, was fully repaid by ICL.

During 2020 and 2021, a related party of the Company, and its affiliates, purchased 2,100,800 common units of Rani LLC and 7,880,120 Series E Preferred Units of Rani LLC. As part of the Organizational Transactions the common units and Series E Preferred Units were exchanged for 5,277,729 shares of the Company's Class A common stock. In connection with the IPO and subsequent thereto, the same related party purchased an additional 6,458,904 shares of the Company’s Class A common stock for total gross proceeds of $71.1 million.

Exclusive License, Intellectual Property and Common Unit Purchase Agreement

The Company, through Rani LLC, and ICL entered into an exclusive license and an intellectual property agreement and common unit purchase agreement in 2012. Pursuant to the common unit purchase agreement, the Company issued 46.0 million common units to ICL in return for rights to exclusive commercialization, development, use and sale of certain products and services related to the RaniPill capsule technology. ICL also granted the Company a fully-paid, royalty-free, sublicensable, exclusive license under the intellectual property made by ICL during the course of providing services to the Company related to the RaniPill capsule technology. Such rights were not recorded on the Company’s condensed consolidated balance sheet as the transaction was considered a common control transaction.

In June 2021, ICL and the Company, through Rani LLC, entered into an Amended and Restated Exclusive License Agreement which replaced the 2012 Exclusive License Agreement between ICL and Rani LLC, as amended in 2013, and terminated the 2012 Intellectual Property Agreement between ICL and Rani LLC, as amended in June 2013. Under the Amended and Restated Exclusive License Agreement, the Company has a fully paid, exclusive license under certain scheduled patents related to optional features of the device and certain other scheduled patents to exploit products covered by those patents in the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. The Company covers patent-related expenses and, after a certain period, the Company will have the right to acquire four specified United States patent families from ICL by making a one-time payment of $0.3 million to ICL for each United States patent family that the Company desires to acquire, up to $1.0 million in the aggregate. This payment will not become an obligation until the fifth anniversary of the Amended and Restated Exclusive License Agreement. The Amended and Restated Exclusive License Agreement will terminate when there are no remaining valid claims of the patents licensed under the Amended and Restated Exclusive License Agreement. Additionally, the Company may terminate the Amended and Restated Exclusive License Agreement in its entirety or as to any particular licensed patent upon notification to ICL of such intent to terminate.

Non-Exclusive License Agreement between Rani and ICL (“Non-Exclusive License Agreement”)

In June 2021, the Company, through Rani LLC, entered into the Non-Exclusive License Agreement with ICL a related party, pursuant to which the Company granted ICL a non-exclusive, fully-paid license under specified patents that were assigned from

16


 

ICL to the Company. Additionally, the Company agreed not to license these patents to a third party in a specific field outside the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine, if ICL can prove that it or its sublicensee has been in active development of a product covered by such patents in that specific field. ICL may grant sublicenses under this license to third parties only with the Company’s prior approval. The Non-Exclusive License Agreement will continue in perpetuity unless earlier terminated.

Intellectual Property Agreement with Mir Imran (the “Mir Agreement”)

In June 2021, the Company, through Rani LLC, entered into the Mir Agreement, pursuant to which the Company and Mir Imran agreed that the Company would own all intellectual property conceived (a) using any of the Company’s people, equipment, or facilities or (b) that is within the field of oral delivery of sensors, small molecule drugs or biologic drugs including, any peptide, antibody, protein, cell therapy, gene therapy or vaccine. Neither the Company nor Mir Imran may assign the Mir Agreement to any third party without the prior written consent of the other party. The initial term of the Mir Agreement is three years, which can be extended upon mutual consent of the parties. The Mir Agreement may be terminated by either party for any reason within the initial three year term upon providing three months’ notice to the other party.

Secondary Sales Transactions

In February 2021, one of the Company's named executive officers and then member of the Board of Managers of Rani LLC, and a current member of the Board of Managers of Rani LLC sold a total of 210,000 common units to a third-party investor at $7.1471 per unit. The Company determined that the sales price was above fair value of such units and as a result recorded equity-based compensation expense of $0.5 million for which $0.2 million was recorded as general and administrative expense and $0.3 million was recorded as research and development expense. The $0.5 million represents the difference between the sales price and fair value of the common units.

 

Tax Receivable Agreement

Certain parties to the TRA, entered into in August 2021 pursuant to the IPO and Organizational Transactions are related parties of the Company. The TRA provides that the Company pay to such entities and individuals 85% of the amount of tax benefits, if any, it is deemed to realize from exchanges of Paired Interests (Note 2). During the three months ended March 31, 2022, these parties to the TRA exchanged 2,309,490 Paired Interests that resulted in tax benefits subject to the TRA (Note 10).

 

Registration Rights Agreement

In connection with the IPO, the Company entered into a Registration Rights Agreement. ICL and its affiliates are parties to this agreement. The Registration Rights Agreement provides certain registration rights whereby, at any time following the IPO and the expiration of any related lock-up period, ICL and its affiliates can require the Company to register under the Securities Act of 1933, as amended (the “Securities Act”) shares of Class A common stock issuable to ICL and its affiliates upon, at the Company’s election, redemption or exchange of their Paired Interests. The Registration Rights Agreement also provides for piggyback registration rights. In March 2022, certain holders of our Class A common stock considered to be related parties were made parties to the Registration Rights Agreement.

Rani LLC Agreement

The Company operates its business through Rani LLC and its subsidiary. In connection with the IPO, the Company and the Continuing LLC Owners, including ICL and its affiliates, entered into the Rani LLC Agreement. The governance of Rani LLC, and the rights and obligations of the holders of LLC Interests, are set forth in the Rani LLC Agreement. As Continuing LLC Owners, ICL and its affiliates are entitled to exchange, subject to the terms of the Rani LLC Agreement, Paired Interests for Class A common stock of the Company; provided that, at the Company’s election, the Company may effect a direct exchange of such Class A common stock or make a cash payment equal to a volume weighted average market price of one share of Class A common stock for each Paired Interest redeemed.

During the three months ended March 31, 2022, entities affiliated with ICL exchanged